Suppr超能文献

心房颤动和药物治疗:普罗帕酮的作用。

Atrial fibrillation and the pharmacological treatment: the role of propafenone.

机构信息

Department of Cardiology, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy.

出版信息

Eur Rev Med Pharmacol Sci. 2012 Feb;16(2):242-53.

Abstract

BACKGROUND

Atrial fibrillation is the most frequent cardiac rhythm disturbance, with prevalence increasing with age. This disease is a major risk factor for ischaemic stroke. The costs resulting from atrial fibrillation are really impressive. Pharmacological agents are the first line therapy for the management of atrial fibrillation. Antiarrhythmic drugs are used to terminate arrhythmias, as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. Among antiarrhythmic agents, drugs that inhibit early sodium current (as propafenone) are proven effective in atrial fibrillation. In this review, the most relevant data on propafenone are provided.

DISCUSSION

The development of a sustained-release formulation of propafenone allowed to reduce the wide fluctuations in plasma levels observed with the immediate release preparation, improving compliance and adherence to therapy, by simplifying the dosing regimen from 3 to 2 daily doses. Propafenone resulted an effective measure as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. In several clinical studies, strong increases of arrhythmia-free periods as well as marked increases in time to recurrence of symptomatic atrial fibrillation, such as paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation were observed. In particular, well-designed clinical studies demonstrated in large patient populations the efficacy of propafenone at several doses. At the suggested doses propafenone is usually well tolerated.

CONCLUSION

The risk of increased occurrence of regular supraventricular arrhythmia or paroxysmal supraventricular tachycardia has been overestimated for propafenone, because this adverse event was seen in all treatment groups, including placebo, with the same (and low) frequency.

摘要

背景

心房颤动是最常见的心律失常,其患病率随着年龄的增长而增加。这种疾病是缺血性中风的一个主要危险因素。心房颤动所导致的成本非常可观。药物是管理心房颤动的一线治疗方法。抗心律失常药物用于终止心律失常,作为近期发作的心房颤动急性治疗,以及维持窦性节律,作为预防心房颤动复发的慢性治疗。在抗心律失常药物中,抑制早期钠电流的药物(如普罗帕酮)已被证明对心房颤动有效。在这篇综述中,提供了关于普罗帕酮的最相关数据。

讨论

普罗帕酮的缓释制剂的开发使得可以减少即时释放制剂中观察到的血浆水平的广泛波动,通过将剂量方案从 3 次/天简化为 2 次/天,从而提高了顺应性和对治疗的依从性。普罗帕酮作为近期发作的心房颤动的急性治疗和维持窦性节律的慢性治疗,对预防心房颤动复发是有效的。在几项临床研究中,观察到心律失常无发作期的显著增加以及症状性心房颤动复发的时间(如阵发性室上性心动过速和阵发性心房颤动)的显著增加。特别是,精心设计的临床研究在大量患者群体中证明了普罗帕酮在几种剂量下的疗效。在建议的剂量下,普罗帕酮通常耐受性良好。

结论

普罗帕酮发生规则性室上性心律失常或阵发性室上性心动过速的风险被高估了,因为这种不良事件在所有治疗组中都出现了,包括安慰剂组,其发生率相同(且较低)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验